Legal Representation
Attorney
Chelsea E. Carbone
Application History
38 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Aug 11, 2025 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED | Loading... |
| Aug 11, 2025 | COAR | I | TEAS CHANGE OF OWNER ADDRESS RECEIVED | Loading... |
| Aug 11, 2025 | CHAN | I | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | Loading... |
| Aug 11, 2025 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | Loading... |
| Aug 11, 2025 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | Loading... |
| May 21, 2024 | NRCC | E | NOTICE OF REGISTRATION CONFIRMATION EMAILED | Loading... |
| May 21, 2024 | R.PR | A | REGISTERED-PRINCIPAL REGISTER | Loading... |
| Apr 17, 2024 | SUNA | E | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED | Loading... |
| Apr 16, 2024 | CNPR | P | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED | Loading... |
| Mar 23, 2024 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Mar 22, 2024 | SUPC | I | STATEMENT OF USE PROCESSING COMPLETE | Loading... |
| Mar 22, 2024 | DPCC | D | DIVISIONAL PROCESSING COMPLETE | Loading... |
| Mar 22, 2024 | EX1G | S | SOU EXTENSION 1 GRANTED | Loading... |
| Feb 29, 2024 | AITU | A | CASE ASSIGNED TO INTENT TO USE PARALEGAL | Loading... |
| Feb 6, 2024 | EISU | I | TEAS STATEMENT OF USE RECEIVED | Loading... |
| Feb 6, 2024 | IUAF | S | USE AMENDMENT FILED | Loading... |
| Feb 6, 2024 | DRRR | I | DIVISIONAL REQUEST RECEIVED | Loading... |
| Feb 6, 2024 | ERTD | I | TEAS REQUEST TO DIVIDE RECEIVED | Loading... |
| Feb 5, 2024 | EXT1 | S | SOU EXTENSION 1 FILED | Loading... |
| Feb 5, 2024 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Aug 22, 2023 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Jun 27, 2023 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Jun 27, 2023 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Jun 7, 2023 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| May 25, 2023 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| May 25, 2023 | XAEC | I | EXAMINER'S AMENDMENT ENTERED | Loading... |
| May 25, 2023 | GNEA | O | EXAMINERS AMENDMENT E-MAILED | Loading... |
| May 25, 2023 | GNEN | O | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | Loading... |
| May 25, 2023 | CNEA | R | EXAMINERS AMENDMENT -WRITTEN | Loading... |
| May 24, 2023 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| May 22, 2023 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| May 22, 2023 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Feb 23, 2023 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Feb 23, 2023 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Feb 23, 2023 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Feb 8, 2023 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Apr 27, 2022 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Apr 25, 2022 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 042
Providing temporary use of non-downloadable computer software using artificial intelligence (AI) and machine learning for analyzing immune data for the purposes of medical research, diagnosis, and treatment; providing temporary use of non-downloadable computer software using artificial intelligence (AI) and machine learning for analyzing immune data for the purposes of identifying, prescribing and monitoring medications; providing temporary use of non-downloadable computer software using artificial intelligence (AI) and machine learning for diagnosing, monitoring and treating diseases and disorders, namely, infectious disease, cancer, autoimmune disorders, cardiovascular disease, and neurological disorders; scientific research and development; pharmaceutical research and development; medical research; medical and pharmaceutical research services; cloud hosting provider services for storing, analyzing and sharing biological information; providing an online network environment service featuring technology that enables users to store, analyze and share data in the fields of life science; technical support services, namely, infrastructure management services for monitoring, administration and management of cloud computing IT and application systems in the fields of life science; product design and development of laboratory apparatus and instruments and design and development of computer software systems for use in analysis of biomolecules; installation and maintenance of computer software and software databases used in the field of analysis of biomolecules; consultancy, information, and advisory services in the field of medical research analysis of biomolecules, diseases, disorders, and treatment efficacy; product development, namely, developing equipment for use in preparing, detecting, sequencing, quantifying, and analyzing proteins and other biological molecules, and automated laboratory equipment and systems, and computer systems for collecting, storing, analyzing, and reporting biological information, and for sample tracking and managing projects, laboratory workflow and data to the order and specification of others, all the foregoing in the fields of scientific and clinical research; medical and scientific research in the fields of vaccines, pharmaceuticals, biologics, vaccines, adjuvants, adjuvant formulations, biologic formulations, drug delivery, diagnostics, and medical therapeutics; product research and development in the fields of pharmaceuticals, vaccines, diagnostics, adjuvants, adjuvant formulations, biologic formulations, and drug delivery; custom design and development of chemical reagents and biochemical assays; testing of pharmaceuticals; scientific laboratory services; computer and scientific research in the field of artificial intelligence (AI) and machine learning for analysis of immune data, disease states, and treatment response
First Use Anywhere:
20230500
First Use in Commerce:
20230500
Class 044
Medical testing and reporting for diagnostic or treatment purposes; consultancy, information, and advisory services in the field of medical treatment of infectious disease, cancer, autoimmune disorders, cardiovascular disease, and neurological disorders
First Use Anywhere:
20230500
First Use in Commerce:
20230500
Classification
International Classes
042
044